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In North America, approximately 700,000 cases of sep-
sis occur each year, with mortality ranging between
30% and 50%. The American Journal of Pathology has
featured numerous articles on the topic, revealing
mechanistic insights gleaned from both experimental
rodent models and human sepsis. Nonetheless, there
remains urgent need to determine the basis for sepsis-
related complications and how they can be avoided, as
well as how they can be most effectively treated once
recognized. This historical perspective reviews what we
currently understand about the mechanisms of sepsis,
as well as the barriers that remain in our treatment
strategies. (Am J Pathol 2012, 181:2–7; http://dx.doi.org/
10.1016/j.ajpath.2012.05.003)
Over the years, The American Journal of Pathology has
published a number of articles dealing with mechanisms
of experimental sepsis in rodents (eg, endotoxemia and
polymicrobial sepsis induced by cecal ligation and punc-
ture [CLP]). Studies in experimental sepsis have ad-
dressed the roles of peroxisome proliferator-activated re-
ceptors (PPARs)1 and high mobility group B1 (HMGB1) in
septic mice,2 abnormal levels of ICAM-1 and VCAM-1 in
septic lungs,3 exacerbation of lung inflammatory re-
sponses in mice that have recovered from sepsis,4 the
role of matrix metalloproteinases (MMPs) in the septic
heart,5 and the genomic signatures of sepsis in rodents.6
Such a range of articles suggests considerable research
dealing with the pathophysiology of sepsis.
There is no question that sepsis has several features
common to both rodents and humans, including exces-
sive systemic production of reactive oxygen species and
reactive nitrogen species,7 a hyperinflammatory state de-
fined by the presence of numerous proinflammatory me-
diators appearing in plasma (referred to as the systemic
inflammatory response syndrome, or SIRS, which occurs
also in response to noninfectious insults),8 and increased
expression of adhesion molecules on monocytes, macro-
phages, and polymorphonuclear neutrophils and on endo-
thelial cells, as well as increased presence of receptors on
leukocytes reactive with cytokines and chemokines.3,9Such findings suggest enhanced mobilization of leukocytes
2into tissues and organs, perhaps resulting in progressive
development of septic shock and multiorgan failure, and
ultimately death. In addition, for both mice and humans, in
sepsis there is development of immunosuppression that
compromises both acute and longer-term survival.10–12 In
North America there are approximately 700,000 cases of
sepsis each year, with a mortality rate ranging between
30% to 50%.13 Most patients with sepsis are admitted to
intensive care units and are on mechanical ventilation, and
the annual costs for the treatment of patients with sepsis are
estimated to exceed $17 billion.13,14
Recent studies have emphasized an aspect of sepsis
that had not previously been recognized: medical prob-
lems developing after patients and laboratory animals
have recovered from sepsis.15–17 These long-term com-
plications, referred to as lingering consequences, in-
clude physical deterioration of skeletal muscle function,
cognition impairment, changes in affective behavior, and
persistent immunosuppression.17 What causes these
long-term complications is a total mystery. In septic mice,
the long-term immunosuppressive state may, at least in
part, be reversible by infusion of dendritic cells.18 Clinical
observations suggest that, over time, sepsis induces se-
rious consequences that may require extended medical
support. In other words, for some patients who have
recovered from sepsis there may nonetheless be pro-
gressive, disabling outcomes. There is urgency in the
need to determine the basis for these complications and
how they can be avoided, as well as how they can most
effectively be treated once recognized.
The Disconnect between Outcomes of
Studies in Septic Rodents and Outcomes
of Clinical Trials in Sepsis
Clinical trials in sepsis have often been based on antag-
onizing mediators of the systemic inflammatory response,
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vivo neutralization. After studies in rodents, investigation
progressed to humans with sepsis. Some of the most
commonly selected targets in septic mice have been
TNF- and its multiple receptors, including IL-1, IL-12,
IL-18, and HMGB1.19 Therapeutic strategies in humans
have involved use of neutralizing, humanized monoclonal
antibodies. In addition, mechanical devices have been
developed to remove a variety of cytokines, lipopolysac-
charide, or C5a from plasma of septic animals.20,21 Al-
though there is limited evidence that this technology will
significantly and persistently reduce mediator levels in
plasma, it is too early to know whether such devices
would be clinically efficacious for sepsis in humans.19
Other targets for neutralization in sepsis have included
thrombogenic products, such as activated tissue factor
and activated clotting factors V and VIII. Although such
interventions showed some efficacy in septic mice, in
human clinical trials the interventions were ineffective.19
Activated protein C, an antithrombotic serine protease,
has been used as a drug for treatment of sepsis in hu-
mans. Recombinant activated human protein C [drotre-
cogin  (Xigris; Eli Lilly, Indianapolis, IN)] is itself an
antithrombotic agent, but has additional effects that are
anti-inflammatory.22 Initial clinical trials with drotrecogin 
showed some limited efficacy, slightly improving 28-day-
survival in sepsis patients. One adverse effect in treat-
ment with drotrecogin  is an increased risk of hemor-
rhagic events. Because many humans with sepsis
develop consumptive coagulopathy or have other under-
lying risks for bleeding complications, several limitations
have been placed on the use of drotrecogin  for sepsis
in humans (eg, platelet counts  30,000/L and no his-
tory of recent major bleeding events). A few years ago,
drotrecogin  was assessed for use in infants and chil-
dren with severe sepsis (defined as SIRS with organ
dysfunction or shock), but the clinical trials were sus-
pended when an increased incidence of intracranial
hemorrhage developed in pediatric patients treated with
drotrecogin  (U.S. Food and Drug Administration, http://
www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm152833.htm,
last updated June 19, 2009, last accessed May 22,
2012). Based on a recent (third) clinical trial in septic
adults, drotrecogin  was found to be nonefficacious,
such that Eli Lilly and the FDA jointly agreed to remove
drotrecogin  from the market (U.S. Food and Drug Ad-
ministration, http://www.fda.gov/Safety/MedWatch/
Safety In format ion/SafetyA ler ts forHumanMedica l
Products/ucm277143.htm, last updated October 25, 2011,
last accessed May 22, 2012).23
In short, this means that currently there are no FDA-
approved drugs specific for the treatment of sepsis in
humans.
How, and why, have we experienced such frustrating
outcomes after enormous expenditures for basic re-
search and for the conduct of clinical trials in sepsis? In
the case of mice with endotoxemia, it has been sug-
gested that this model may not be relevant to the patho-
physiology of human sepsis.19,24,25 There have also been
concerns that mouse models use young mice with nocomorbidities, which is in marked contrast to adult hu-
mans with sepsis, who are often over the age of 60 years
and present with comorbidities. Another problem has
been inconsistency in experimental protocols across
studies as related to fluid resuscitation and use of antibi-
otics (or lack thereof) in septic mice. In contrast, sepsis
patients routinely receive these interventions; they also
typically have comorbidities (eg, heart disease, hyperten-
sion, diabetes mellitus, and the like) and are on comedi-
cations. Furthermore, designs of human clinical trials in
sepsis vary substantially with respect to patient selection
for enrollment. Such trials almost always use survival at
28 days as the key endpoint (based on FDA criteria).19,25
Setting the endpoint as survival rates at 28 days ignores
the possibility that some interventions significantly im-
prove clinical manifestations over the first 10 days of
sepsis. Furthermore, for clinical trials in which nearly two
thirds of patients will survive (unless patient selection
criteria are more selective) this will translate into individ-
ual clinical trials requiring thousands of patients, making
such trials extraordinarily expensive.
A Current Perspective on Sepsis Mechanisms
Our current perspective on sepsis mechanisms includes
the roles of T and B cells in sepsis, as well as the appar-
ent roles of natural killer (NK) cells8 and dendritic cells
(DCs) and how these cells become dysfunctional in the
course of sepsis. We also describe development of
apoptosis of T and B cells during sepsis and controver-
sies related to interpretation of data from sepsis models
in laboratory animals.
Defects of T and B Cells, NK Cells, and
Dendritic Cells in Sepsis
The role of T and B cells in sepsis is not devoid of
controversy. Despite extensive evidence suggesting that
T and B cells play important protective roles in polymi-
crobial sepsis, a recent report describes the outcomes
after CLP in Rag1/ mice, which lack both B and T
cells.26 The Rag1/ mice have survival curves similar to
wild-type mice, and, in general, plasma levels of proin-
flammatory mediators are similar in Rag1/ and wild-
type mice after CLP. Although the initial interpretation is
that T and B cells are dispensable in protection against
sepsis, there is another explanation. It is possible that
these Rag1 knockout mice, which are profoundly immu-
nodeficient, have orchestrated some type of accommo-
dation during their development and maturation that re-
sults in adjustment to the absence of T and B cells, at
least in the setting of polymicrobial sepsis.
Published evidence suggests that apoptosis-depen-
dent deletion of both B and T cells occurs early in sepsis,
especially in humans. A recent study using autopsy
specimens and focusing exclusively on sepsis in humans
demonstrated extensive apoptosis of both T and B cells,
which was accompanied by evidence of profound immu-
nosuppression.10 Analysis of lipopolysaccharide-stimu-
lated cells obtained from spleen and lung of patients with
4 Ward and Bosmann
AJP July 2012, Vol. 181, No. 1sepsis revealed greatly diminished in vitro production of
TNF-, IFN-, IL-6, and IL-10, with levels generally10%
of those in cell culture supernatant fluids from lipopoly-
saccharide-stimulated cells obtained from age-matched
patients without sepsis. Flow cytometry revealed in-
creased expression on splenocytes of receptors and li-
gands that are T-cell regulators (eg, programmed cell
death protein 1 [PD-1] and its ligands). There were also
increased numbers of T-suppressor cells (T-regulatory
cells) in tissues. As expected, there was extensive tissue
depletion of CD4, CD8, and HLA-DR cells. Collec-
tively, these studies indicate a loss of T and B cells, due
to apoptosis, and the expression of receptors and li-
gands that inhibit T-cell-dependent immune responses.
Attempts have been made in mice to reverse the immu-
nosuppressive state in sepsis, using synthetic inhibitors
of apoptosis, which we describe below.
B Cells
B cells are reported to enhance early innate immune
responses in CLP mice.27 It was postulated that under
these circumstances B cells are protective in an IFN--
dependent manner. Recently, however, a different pro-
tective mechanism for B cells in sepsis has been sug-
gested. A newly recognized subclass of splenic B cells,
termed innate response activator B (IRA-B) cells, has
been shown to be protective in the setting of polymicro-
bial sepsis (induced by CLP).28 These B cells locally
produce GM-CSF, which may in some manner preserve
innate immune functions (eg, phagocytosis, chemotaxis,
and the like) of tissue neutrophils that otherwise lose
these protective functions as the sepsis state develops.
To what extent these B-cell findings in mice are relevant
to sepsis in humans remains to be determined.
T Cells
Development and progression of sepsis is associated
with a variety of derangements in the innate immune and
adaptive immune systems, such as increased T and B
cell apoptosis, diminished Th1 cell function, reduced T
cell receptor (TCR) function, and increased presence of
T-suppressor (T-regulatory cells) cells in tissues.10,29 The
T-cell system is clearly central to the ability of the immune
system to neutralize products, whether intrinsic or extrin-
sic, that trigger the dangerous cascade of events that
develop during sepsis. In addition, there is abundant
evidence that sepsis via generation of the complement
anaphylatoxin C5a also compromises innate immune re-
sponses of phagocytes (eg, chemotaxis and phagocyto-
sis), alongside defective responses of these cells to var-
ious TLR agonists.30 It seems clear that a sepsis-induced
cascade of events leads to immunosuppression. As will
be briefly discussed, interventions under consideration
are designed to i) reduce apoptosis of T and B cells and
replace apoptotic T cells or in some manner restore T cell
function, ii) restore innate immune functions of defective
phagocytic cells, and iii) restore DC functions.NK Cells
NK cells are defined by surface markers (CD3,
NKp46, CD56) that reflect their cytotoxic properties
and also by production of cytokines, including IFN-. NK
cells may yield protective effects in sepsis, but they may
also contribute to some of the harmful consequences of
sepsis.31,32 NK cells play a major role in host defenses
against residential viruses, such as herpesvirus and cy-
tomegalovirus. These viruses often emerge as a result of
sepsis-induced immunosuppression. There is additional
evidence that NK cells are important for in vivo contain-
ment of organisms such as Streptococcus pneumoniae,
Escherichia coli, Toxoplasma gondii, and Listeria monocy-
togenes. In a way, one could posit that NK cells function
in a manner similar to that of Th17 cells in containing the
infectious agents (eg, bacteria, fungi) that tend to emerge
in immunocompromised individuals.32 In the early
phases of septic shock, NK cells may contribute to an
overactive immune response and development of sys-
temic inflammation, which appear to be detrimental to
survival. In the later phases of sepsis, however, NK cells
may provide protection against development of second-
ary bacterial infections as the immunosuppressive con-
dition intensifies. In the face of such contrasting effects,
there is no consensus on whether NK cells should be
therapeutically manipulated in sepsis.
Dendritic Cells
It has been known for some time that DCs are protec-
tive in mice with polymicrobial sepsis (induced by CLP)
and that sepsis causes depletion of splenic and myeloid
DCs, whereas the remaining DCs have been rendered
functionally deficient and show poor production of IL-
12—all of which predicts poor survival.4,33,34 It also ap-
pears that CLP induces depletion of DCs via interaction
of TLR2 and TLR4 with their relevant ligands.35 Although
DCs serve as a major source of antigen presentation to T
cells, they also produce IL-12 and IL-10 and express on
their surfaces MHCII and CD86 (an immune costimula-
tory molecule). Moldawer and colleagues33 have sug-
gested that DCs function to bridge innate and acquired
immune systems. Finally, infusion of bone marrow-de-
rived DCs into mice with polymicrobial sepsis markedly
improves survival, consistent with protective functions of
DCs in sepsis.18,33–35 This raises the question of
whether infusion of DCs into sepsis patients may rep-
resent a strategy to reverse the state of immunosup-
pression (although problems related to histocompati-
bility present substantial obstacles).
Mechanisms of Apoptosis of T and B Cells in
Sepsis
As we have indicated above, there is strong evidence
that the immunosuppressive outcomes of sepsis can be
linked at least in part to apoptosis of the lymphoid system
(T and B cells in humans, together with thymocytes in
rodents). In the case of apoptosis of thymocytes in CLP
rats, this is linked to the trigger, C5a, interacting with its
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this example of apoptosis, there appears to be a domi-
nant role for activation of the intrinsic (mitochondrial)
pathway of apoptosis.36 In polymicrobial sepsis, there is
also apoptosis of gastrointestinal epithelial cells, possibly
setting the stage for translocation of Gram-negative bac-
teria and their breakdown products into the draining lym-
phatic system and hence into the bloodstream. Other
studies suggest that the pathways leading to apoptosis
during sepsis involve both the extrinsic pathway (Fas/
Fas-ligand and TNF/TNF-receptors) and the intrinsic (mi-
tochondrial) pathway.36–38 Naturally occurring inhibitors
of apoptosis (Bcl-2) as well as synthetic inhibitors of
caspases have been used in the setting of polymicrobial
sepsis in mice. AlthoughMyd88/ mice (with deletion of
an adaptor protein common to many TLRs) exhibit dimin-
ished apoptosis of T and B cells after CLP, overall sur-
vival is reduced.39
Some evidence40 exists that apoptotic pathways are
also involved in cell proliferation and related functions,
which raises a concern that excessive inhibition of
caspase pathways may, on balance, be harmful. The
other constraining feature related to inhibition of apopto-
Figure 1. Onset of sepsis beginning either as bacterial pneumonia or as perit
include apoptotic deletion of T and B cells, defective DCs, and onset of imm
of the ability to clear bacteria, resulting in development of multiorgan failur
a variety of cells (leukocytes) and organs due to buildup of reactive oxygen specie
sustained immune response and other immune activation states in endothelial cellssis in the setting of sepsis is the fact that, by the time they
are admitted to an intensive care unit, most patients with
sepsis are already significantly lymphopenic.41 This sug-
gests that, for interventions aimed at suppressing apop-
tosis and intended to be applied at the time of admission
of patients with sepsis to the intensive care unit, it may be
too late for effective reversal of the apoptotic state. Ac-
cordingly, it has been suggested that the use of immu-
nostimulants (eg, IL-7) might be able to revive the im-
mune system (although this remains to be demonstrated
in humans with sepsis).42
Controversies Related to Sepsis Research
The development of the so-called cytokine storm during
sepsis (triggered after endotoxemia or in polymicrobial
sepsis induced by CLP in rodents and the subject of
some controversy) has been interpreted to represent a
hyperinflammatory response caused by the inability to
regulate activation of the immune system. Consistent with
this view has been emerging evidence that several other
changes developing during sepsis could indicate a hy-
sociated with extramural leaking of intestinal contents. A: Subsequent events
pression, together with defective innate immunity. These events lead to loss
) and death. B: Development of sepsis can also lead to redox imbalance inonitis as
unosup
e (MOFs (ROS). This is followed by an inflammatory response (SIRS), including a
and leukocytes, ultimately associated with MOF and death.
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cell adhesion molecules (ICAM-1) for leukocytes3 and
increased up-regulation of adhesion molecules on
blood leukocytes (1 and 2 integrins), as well as in-
creased expression on leukocytes or chemokine and
cytokine receptors,9 all of which would imply a gain of
function for these cells and intensification of the inflam-
matory response.
If such a hypothesis is correct, then the use of ap-
proaches aimed at neutralizing proinflammatory media-
tors or adhesion molecules on endothelial cells (ICAM-1)
or leukocytes (1 and 2 integrins) in sepsis patients
would seem reasonable. However, in view of the well-
known state of immunosuppression that develops in sep-
sis, such strategies would have to be very judiciously
used in humans. Another problem is the redundancy and
overlapping responses in inflammatory mediators. Nu-
merous clinical trials in humans targeted at neutralizing
proinflammatory mediators or their receptors have failed
(see review by Marshall19). The widespread interest in
the Toll-like receptor (TLR) system playing a role in sepsis
led to recent clinical trials using a potent antagonist to
TLR4, eritoran, but these trials were prematurely termi-
nated in 1500 patients because of lack of evidence for
efficacy (K. Matsuyama, Bloomberg News 2011, http://
www.bloomberg.com/news, posted January 25, 2011,
last accessed May 22, 2012).
There may be a tendency to dismiss these many clin-
ical trials as misguided or inadequately designed, or
because of great overlap and redundancy in functions of
inflammatory mediators and receptors, which would be
an indication that the inflammatory and innate immune
systems are difficult targets for interventions in human
sepsis. If so, attempts to correct the immunosuppressive
state might represent an alternative approach. For now,
no ex cathedra conclusions about design of new clinical
trials in sepsis are possible. It could also be that the
systemic inflammatory response represents a protective
reaction in sepsis, reflecting an inflammatory response
that has been triggered after an inability of the organism
to adequately cope with and to clear offending infectious
agents and/or their products. If there is any truth to this
concept, then a different clinical approach for the treat-
ment of sepsis patients may hold promise, namely, inter-
ventions with immunostimulants such as IL-15 and/or
IL-7, which might restore the incapacitated immune re-
sponse caused by sepsis. There is some evidence in
septic mice suggesting that treatment with IL-7 may be
protective and may enhance the IL-17/Th17 axis.41 Inter-
ventions with IL-7 and/or IL-15 may have some capacity
to reverse the immunosuppressive state in septic mice.
Until appropriate clinical trials in sepsis commence, how-
ever, the question of the reversibility of immune suppres-
sion cannot be answered. Another suggested strategy is
to block receptors or ligands, such as PD-1, that sup-
press T cell activation.43 Nonetheless, given the numer-
ous receptors and ligands that negatively regulate the
immune response and that are up-regulated in patients
with sepsis,10 selection of a single target of this type for
blockade may not be efficacious.Where Do We Go from Here?
Animal models of sepsis and clinical observations in sep-
sis patients suggest three issues related to our current
understanding of sepsis and possible interventions.
1. Progressive onset of immunosuppression relates to
apoptosis of T and B cells, as well as loss of innate
immune functions of leukocytes. The T-cell defects might
be reversed by use of immunostimulants (eg, IL-7, IL-15)
(Figure 1A).
2. An excessive inflammatory response associated
with excessive levels in tissues of reactive oxygen spe-
cies, along with the systemic inflammatory response, re-
sults in multiorgan damage. The containment of a hyper-
inflammatory response is difficult, because of the multitude
of proinflammatory mediators and receptors that have over-
lapping functions. This dilemma reflects our poor under-
standing of the responses in sepsis and the pressing need
for new therapeutic approaches (Figure 1B).
3. The delayed onset of complications of sepsis poses
major problems for recovered patients after sepsis. Be-
cause we do not know the causes of these postrecovery
complications, we are in no position to institute therapies.
Such lingering complications may contribute to defects in
cognition, immune competence, and skeletal muscle
function.17 The basis for these delayed and persistent
complications is not known.
As we have emphasized above, sepsis is a major
medical condition associated with severe morbidity and
high mortality. It is an especially costly medical problem.
Although improvements in supportive care of patients
with sepsis (eg, more effective and less damaging me-
chanical ventilation, improved fluid resuscitation, and
broad-spectrum antibiotic coverage) have improved sur-
vival rates, sepsis remains a condition with high mortality.
Despite many clinical trials, to date no FDA-approved
drug is available for use in sepsis, a lack that under-
scores the importance of future sepsis research.
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